amylases Inhibitors
5 drugsAbout amylases
Amylases are a class of enzymes that catalyze the hydrolysis of starch into sugars, playing a crucial role in carbohydrate digestion within saliva and pancreatic fluid.
Amylases are a clinically validated drug target for managing digestive disorders, though no direct genetic evidence currently links them to specific diseases.
Five FDA-approved drugs, including CREON, ZENPEP, VIOKACE, PERTZYE, and PANCREAZE, target amylases using biologic (other) modalities, focusing on enzyme replacement therapy.
Top amylases Drugs
Five companies have approved amylase-targeting drugs, including AbbVie, EURAND PHARMA LTD and VIOKACE.
The presence of multiple players indicates a competitive market, requiring strong differentiation for new entrants.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| PERTZYE | DIGESTIVE CARE INC | 2012 | 1 |
| CREON | AbbVie | 2009 | 1 |
amylases Drug Modality Landscape
Modalities
Routes of Administration
amylases requires biologic approaches (enzyme), likely due to its structure or location.
The absence of small molecule or antibody amylase drugs suggests a whitespace opportunity for novel modalities.
amylases Clinical Trials 23 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on amylases. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 0 | 3 | 1 | 0% |
| Phase 2 | 6 | 1 | 2 | 3 | 33% |
| Phase 3 | 2 | 1 | 1 | 0 | 50% |
| Phase 4 | 11 | 4 | 6 | 1 | 40% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
amylases Drug Approval Timeline (2009 - 2012)
The first amylase-targeting drug was approved in 2009 (CREON), with the most recent approval in 2012 (PERTZYE).
The limited approval span suggests market saturation or challenges in developing new amylase-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 5 companies competing
- • Market share by company
Full Drug Portfolio
- • All 5 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 5-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 17 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on amylases. A trial counts if an approved drug acting on amylases is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.